Blog

Submitted Case

2022
1. Submitted Case
2. Submitted Case
3. Submitted Case
4. Peer Review
5. Submitted Case
6. Submitted Case
7. Submitted Case
8. Submitted Case
9. Peer Review
10. Submitted Case
11. Submitted Case
12. Submitted Case
13. Submitted Case
14. Submitted Case
15. Submitted Case
16. Submitted Case
17. Submitted Case
18. Submitted Case
19. Submitted Case
20. Submitted Case
21. Submitted Case
22. Submitted Case
23. Submitted Case
24. Submitted Case
25. Submitted Case
26. Submitted Case
27. Submitted Case
28. Submitted Case
29. Submitted Case
30. Submitted Case
31. Submitted Case
32. Peer Review
33. Peer Review
34. Peer Review
35. Peer Review
36. Peer Review
37. Submitted Case
38. Submitted Case
39. Submitted Case
40. Peer Review
41. Submitted Case
42. Peer Review
43. Submitted Case
44. Submitted Case
Patient Information: (Do not provide name of the patient)
Age
  67
Diagnosis
  metastatic renal cell carcinoma
Imaging
  CT Head shows destructive mass involving right temporal bone 4×3.5cm
Pathology
  Renal cell with clear cell features
Stage
  IV
Overall Oncology Management Plan
Chemotherapy (if given, what is the regimen)
  lenvatinib + pembrolizumab 6/13 – 6/26; then pembrolizumab alone (did not tolerate first regimen)
Radiation Treatment Plan
Defining target and margin
  Right temporal bone mass
Dose/fractionation
  SRT vs. conventional fractionation
Images
Upload Image
 
 
Session Name
  Head & Neck Specialist Dr. David Sher- Aug. 1st rescheduled from July 25, 2022
Session ID
  12089
created_by
  9311
post_id
  12089
Back To Top